Blood tests for tumor DNA in adults with large B-cell lymphoma
Studies tumor DNA in blood of adults newly diagnosed with aggressive lymphoma.
Plain-language title generated from the registry record
Registry title: Prospective ctDNA Testing in Large B-Cell Lymphoma
Key facts
- Where
- Beijing, ChinaSee the 2 sites
Where in China
- Beijing Tongren HospitalBeijing, ChinaTaking people
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07878351
- Record updated
- 16 October 2026
- Original description
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment. PET/CT is used to assess treatment response, but it may not identify small amounts of residual lymphoma.Read full original descriptionShow less
Circulating Tumor DNA Testing in Patients With Large B-Cell Lymphoma: A Prospective Study
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment. PET/CT is used to assess treatment response, but it may not identify small amounts of residual lymphoma.
Circulating tumor DNA (ctDNA) consists of tumor-derived DNA fragments detectable in blood. This prospective observational study will use PhasED-seq to assess plasma ctDNA before, during, and after first-line therapy in approximately 100 patients with newly diagnosed DLBCL or HGBL.
The primary objective is to evaluate the association between ctDNA status approximately 8 weeks after completion of first-line therapy and subsequent progression-free survival. Additional analyses will examine overall survival, earlier ctDNA findings, and baseline tumor molecular subtypes. PET/CT findings will provide complementary information for exploratory analyses. The findings may inform future studies of response-adapted treatment.
Inclusion: Age ≥18 years, either sex; Histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL); Planned to receive standard immunochemotherapy including at least CD20 monoclonal antibody and anthracycline, such as Pola-RCHP, R-CHOP, or R-DA-EPOCH; No maintenance therapy planned after completion of first-line treatment; Written informed consent obtained.
Exclusion: Prior chemotherapy, targeted therapy, or immunotherapy for large B-cell lymphoma; Concomitant other malignancies; DLBCL/HGBL transformed from indolent B-cell lymphoproliferative disorders; HIV-positive large B-cell lymphoma; Investigator-assessed ineligibility for this study.